CO7020855A2 - Proteínas h5, de h5n1 para un nuevo uso medicinal - Google Patents
Proteínas h5, de h5n1 para un nuevo uso medicinalInfo
- Publication number
- CO7020855A2 CO7020855A2 CO14042269A CO14042269A CO7020855A2 CO 7020855 A2 CO7020855 A2 CO 7020855A2 CO 14042269 A CO14042269 A CO 14042269A CO 14042269 A CO14042269 A CO 14042269A CO 7020855 A2 CO7020855 A2 CO 7020855A2
- Authority
- CO
- Colombia
- Prior art keywords
- proteins
- medicinal use
- new medicinal
- new
- medicinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523772P | 2011-08-15 | 2011-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7020855A2 true CO7020855A2 (es) | 2014-08-11 |
Family
ID=46651534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14042269A CO7020855A2 (es) | 2011-08-15 | 2014-02-27 | Proteínas h5, de h5n1 para un nuevo uso medicinal |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20140199337A1 (enExample) |
| EP (1) | EP2744514B1 (enExample) |
| JP (1) | JP2014527526A (enExample) |
| KR (1) | KR101986071B1 (enExample) |
| CN (1) | CN104144699A (enExample) |
| AR (1) | AR088028A1 (enExample) |
| AU (1) | AU2012296834A1 (enExample) |
| BR (1) | BR112014003278A2 (enExample) |
| CA (1) | CA2845040A1 (enExample) |
| CO (1) | CO7020855A2 (enExample) |
| EA (1) | EA201400235A1 (enExample) |
| ES (1) | ES2765073T3 (enExample) |
| MX (1) | MX363464B (enExample) |
| PH (1) | PH12014500369A1 (enExample) |
| WO (1) | WO2013024113A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| EP2958586B1 (en) * | 2013-02-21 | 2018-09-05 | Boehringer Ingelheim Vetmedica GmbH | H5 proteins of h5n1 influenza virus for use as a medicament |
| KR102173999B1 (ko) | 2014-07-17 | 2020-11-04 | 주식회사 만도 | 차량 통신 제어장치 및 방법 |
| UA130511C2 (uk) | 2016-11-03 | 2026-03-11 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Вакцина проти свинячого парвовірусу й вірусу свинячого репродуктивного й респіраторного синдрому та спосіб її одержання |
| US12098166B2 (en) | 2018-11-06 | 2024-09-24 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition against avian influenza virus H5 subtype |
| KR20250080034A (ko) | 2023-11-27 | 2025-06-05 | 주식회사 카브 | 고병원성 조류인플루엔자 바이러스 및 뉴캐슬병 바이러스의 예방 및 백신 조성물 |
| WO2026013162A1 (en) | 2024-07-10 | 2026-01-15 | Boehringer Ingelheim Vetmedica Gmbh | Herpes virus of turkey vector based h5ha vaccine for the treatment and prevention of avian influenza infections in turkeys |
| WO2026013161A1 (en) | 2024-07-10 | 2026-01-15 | Boehringer Ingelheim Vetmedica Gmbh | Prime and boost vaccination for the treatment and prevention of avian influenza infections in avians |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US382425A (en) | 1888-05-08 | Brandt | ||
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4552758A (en) | 1983-12-20 | 1985-11-12 | St. Jude Children's Research Hospital | Human use of avian-human reassortants as vaccines for influenza A virus |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
| CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
| US5690938A (en) | 1989-07-07 | 1997-11-25 | Oravax, Inc. | Oral immunization with multiple particulate antigen delivery system |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| ATE162402T1 (de) | 1990-04-24 | 1998-02-15 | Flustat Pty Ltd | Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff |
| US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
| EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| ATE181108T1 (de) | 1991-08-26 | 1999-06-15 | Immuno Ag | Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5807722A (en) | 1992-10-30 | 1998-09-15 | Bioengineering Resources, Inc. | Biological production of acetic acid from waste gases with Clostridium ljungdahlii |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| EP0620277A1 (en) | 1993-03-18 | 1994-10-19 | Merck & Co. Inc. | Nucleic acid pharmaceuticals |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| ES2243937T3 (es) | 1994-04-29 | 2005-12-01 | Baxter Healthcare S.A. | Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños. |
| AU711702B2 (en) | 1995-03-23 | 1999-10-21 | Cambridge University Technical Services Limited | Vectors for gene delivery |
| AU737243B2 (en) | 1996-07-03 | 2001-08-16 | Merial, Inc. | Recombinant canine adenovirus (CAV) containing exogenous DNA |
| US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| AU5921101A (en) | 2000-04-28 | 2001-11-12 | St Jude Childrens Res Hospital | Dna transfection system for the generation of infectious influenza virus |
| US20020095197A1 (en) | 2000-07-11 | 2002-07-18 | Lardo Albert C. | Application of photochemotherapy for the treatment of cardiac arrhythmias |
| WO2002062381A1 (en) | 2001-02-05 | 2002-08-15 | Hisamitsu Pharmaceutical Co., Inc. | Baculovirus vector vaccine |
| EP1413315A4 (en) | 2001-08-03 | 2006-08-16 | Takeda Pharmaceutical | DRUGS WITH CONTINUOUS RELEASE |
| US20040146533A1 (en) * | 2002-08-27 | 2004-07-29 | Miller Timothy J. | Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry |
| EP1633312A4 (en) | 2003-06-16 | 2012-09-26 | Medimmune Llc | INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| US20080254065A1 (en) | 2004-03-09 | 2008-10-16 | Chiron Corporation | Influenza Virus Vaccines |
| WO2005116260A2 (en) | 2004-05-25 | 2005-12-08 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| CN1748795A (zh) | 2004-09-17 | 2006-03-22 | 金宁一 | 多价禽流感重组活载体疫苗 |
| KR20080052509A (ko) | 2005-04-11 | 2008-06-11 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 | 유행성 독감 바이러스에 대한 백신 |
| US7871626B2 (en) | 2005-08-04 | 2011-01-18 | St. Jude Children's Research Hospital | Modified influenza virus for monitoring and improving vaccine efficiency |
| PT1937301E (pt) | 2005-10-18 | 2015-09-14 | Novavax Inc | Partículas idênticas a vírus (vlps) da gripe funcionais |
| BRPI0617952A2 (pt) * | 2005-10-28 | 2011-08-09 | Boehringer Ingelheim Vetmed | composição antigênica compreendendo um antìgeno de um patógeno de um animal de uma primeira espécie, bem como uso de vacinas para o tratamento/prevenção da transmissão de patógenos da gripe entre espécies |
| US20100150941A1 (en) * | 2006-09-13 | 2010-06-17 | Dso National Laboratories | Hemagglutinin antibody and uses thereof |
| US8202967B2 (en) * | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| UA99117C2 (ru) * | 2006-10-27 | 2012-07-25 | Берингер Ингельхайм Ветмедика, Инк. | Белок h5 вируса гриппа, молекула нуклеиновой кислоты и кодирующий её вектор, и их применение |
| US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| EP2563389B1 (en) | 2010-04-30 | 2015-07-08 | Temasek Life Sciences Laboratory Limited | Universal vaccine against h5n1 lineages |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| EP2958586B1 (en) | 2013-02-21 | 2018-09-05 | Boehringer Ingelheim Vetmedica GmbH | H5 proteins of h5n1 influenza virus for use as a medicament |
-
2012
- 2012-08-14 AR ARP120102979A patent/AR088028A1/es unknown
- 2012-08-15 CN CN201280045059.1A patent/CN104144699A/zh active Pending
- 2012-08-15 EA EA201400235A patent/EA201400235A1/ru unknown
- 2012-08-15 KR KR1020147006803A patent/KR101986071B1/ko active Active
- 2012-08-15 US US14/238,796 patent/US20140199337A1/en not_active Abandoned
- 2012-08-15 WO PCT/EP2012/065940 patent/WO2013024113A1/en not_active Ceased
- 2012-08-15 PH PH1/2014/500369A patent/PH12014500369A1/en unknown
- 2012-08-15 CA CA2845040A patent/CA2845040A1/en not_active Abandoned
- 2012-08-15 JP JP2014525440A patent/JP2014527526A/ja active Pending
- 2012-08-15 EP EP12746361.0A patent/EP2744514B1/en active Active
- 2012-08-15 MX MX2014001754A patent/MX363464B/es unknown
- 2012-08-15 BR BR112014003278A patent/BR112014003278A2/pt not_active IP Right Cessation
- 2012-08-15 AU AU2012296834A patent/AU2012296834A1/en not_active Abandoned
- 2012-08-15 ES ES12746361T patent/ES2765073T3/es active Active
-
2014
- 2014-02-27 CO CO14042269A patent/CO7020855A2/es unknown
-
2017
- 2017-07-28 US US15/662,358 patent/US10369211B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2744514A1 (en) | 2014-06-25 |
| AU2012296834A1 (en) | 2014-01-23 |
| ES2765073T3 (es) | 2020-06-05 |
| CN104144699A (zh) | 2014-11-12 |
| US20140199337A1 (en) | 2014-07-17 |
| MX2014001754A (es) | 2014-08-26 |
| AR088028A1 (es) | 2014-05-07 |
| WO2013024113A1 (en) | 2013-02-21 |
| CA2845040A1 (en) | 2013-02-21 |
| US20170348413A1 (en) | 2017-12-07 |
| KR101986071B1 (ko) | 2019-06-07 |
| PH12014500369A1 (en) | 2014-04-14 |
| JP2014527526A (ja) | 2014-10-16 |
| EP2744514B1 (en) | 2019-10-16 |
| EA201400235A1 (ru) | 2014-09-30 |
| US10369211B2 (en) | 2019-08-06 |
| BR112014003278A2 (pt) | 2017-03-01 |
| KR20140090137A (ko) | 2014-07-16 |
| MX363464B (es) | 2019-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014001346A2 (pt) | composto nanotransportador, método, composto farmacêutico e uso de um composto | |
| BR112014000260A2 (pt) | composto, e, uso de um composto | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| EP2748685A4 (en) | PORTABLE MEDICINAL DISPENSER | |
| PL3542843T5 (pl) | Pen jednorazowy do wielu zastosowań | |
| DK2706982T4 (da) | Intranasale farmaceutiske dosisformer omfattende naloxon | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| PT4403579T (pt) | Formulação para anticorpos anti-alfa4beta7 | |
| BR112013029206A2 (pt) | composto, e, uso de um composto | |
| CR20130677A (es) | FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7 | |
| BR112013018828A2 (pt) | sistemas de distribuição de droga | |
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| IL230838A0 (en) | Pharmaceutical compositions | |
| BR112013030302A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo | |
| DK2758022T3 (da) | Stiv engangsbeholder til farmaceutiske sammensætninger | |
| BR112013028986A2 (pt) | embalagem para um fluido, e uso de uma embalagem | |
| HUE054072T2 (hu) | A nitrokatecholok adagolási rendje | |
| BR112014006673A2 (pt) | colar de fixação para elementos alongados | |
| BR112013019077A2 (pt) | administração de aerossol controlada pelo paciente | |
| BR112014007641A2 (pt) | uso de um biocida | |
| BR112014002830A2 (pt) | fotossensibilizador para uso terapêutico | |
| BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014008088A2 (pt) | método para detectar anticorpos, uso de um método, e, kit |